Intrinsic value of Quest Diagnostics - DGX

Previous Close

$95.08

  Intrinsic Value

$119.06

stock screener

  Rating & Target

buy

+25%

Previous close

$95.08

 
Intrinsic value

$119.06

 
Up/down potential

+25%

 
Rating

buy

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of DGX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 13.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.29
  2.40
  2.66
  2.89
  3.10
  3.29
  3.46
  3.62
  3.76
  3.88
  3.99
  4.09
  4.18
  4.27
  4.34
  4.41
  4.46
  4.52
  4.57
  4.61
  4.65
  4.68
  4.72
  4.74
  4.77
  4.79
  4.81
  4.83
  4.85
  4.86
  4.88
Revenue, $m
  7,515
  7,695
  7,900
  8,129
  8,381
  8,657
  8,957
  9,281
  9,630
  10,004
  10,403
  10,829
  11,282
  11,763
  12,274
  12,814
  13,386
  13,991
  14,630
  15,304
  16,016
  16,766
  17,557
  18,390
  19,267
  20,190
  21,162
  22,184
  23,260
  24,391
  25,581
Variable operating expenses, $m
 
  6,242
  6,392
  6,560
  6,745
  6,947
  7,167
  7,405
  7,660
  7,934
  8,227
  7,939
  8,271
  8,624
  8,998
  9,395
  9,814
  10,258
  10,726
  11,221
  11,742
  12,292
  12,872
  13,482
  14,126
  14,803
  15,515
  16,265
  17,053
  17,883
  18,755
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  6,238
  6,242
  6,392
  6,560
  6,745
  6,947
  7,167
  7,405
  7,660
  7,934
  8,227
  7,939
  8,271
  8,624
  8,998
  9,395
  9,814
  10,258
  10,726
  11,221
  11,742
  12,292
  12,872
  13,482
  14,126
  14,803
  15,515
  16,265
  17,053
  17,883
  18,755
Operating income, $m
  1,277
  1,453
  1,508
  1,569
  1,636
  1,710
  1,790
  1,877
  1,970
  2,069
  2,176
  2,890
  3,010
  3,139
  3,275
  3,419
  3,572
  3,733
  3,904
  4,084
  4,274
  4,474
  4,685
  4,907
  5,141
  5,388
  5,647
  5,920
  6,207
  6,509
  6,826
EBITDA, $m
  1,526
  2,120
  2,176
  2,239
  2,309
  2,385
  2,467
  2,557
  2,653
  2,756
  2,866
  2,983
  3,108
  3,240
  3,381
  3,530
  3,688
  3,854
  4,030
  4,216
  4,412
  4,619
  4,836
  5,066
  5,307
  5,562
  5,830
  6,111
  6,408
  6,719
  7,047
Interest expense (income), $m
  148
  149
  154
  160
  167
  174
  182
  191
  201
  211
  222
  233
  246
  259
  273
  288
  303
  320
  338
  356
  376
  397
  418
  441
  466
  491
  518
  546
  576
  607
  640
Earnings before tax, $m
  1,125
  1,304
  1,354
  1,409
  1,469
  1,536
  1,608
  1,685
  1,769
  1,859
  1,954
  2,656
  2,765
  2,880
  3,002
  3,132
  3,269
  3,413
  3,566
  3,728
  3,898
  4,077
  4,266
  4,466
  4,675
  4,896
  5,129
  5,373
  5,631
  5,901
  6,186
Tax expense, $m
  429
  352
  365
  380
  397
  415
  434
  455
  478
  502
  528
  717
  746
  778
  811
  846
  883
  922
  963
  1,006
  1,052
  1,101
  1,152
  1,206
  1,262
  1,322
  1,385
  1,451
  1,520
  1,593
  1,670
Net income, $m
  645
  952
  988
  1,028
  1,073
  1,121
  1,174
  1,230
  1,291
  1,357
  1,427
  1,939
  2,018
  2,102
  2,192
  2,286
  2,386
  2,492
  2,603
  2,721
  2,845
  2,976
  3,114
  3,260
  3,413
  3,574
  3,744
  3,923
  4,110
  4,308
  4,516

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  359
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  10,100
  9,981
  10,247
  10,543
  10,870
  11,228
  11,617
  12,038
  12,490
  12,975
  13,493
  14,045
  14,633
  15,257
  15,919
  16,620
  17,362
  18,147
  18,975
  19,850
  20,773
  21,746
  22,771
  23,852
  24,989
  26,187
  27,447
  28,774
  30,169
  31,636
  33,179
Adjusted assets (=assets-cash), $m
  9,741
  9,981
  10,247
  10,543
  10,870
  11,228
  11,617
  12,038
  12,490
  12,975
  13,493
  14,045
  14,633
  15,257
  15,919
  16,620
  17,362
  18,147
  18,975
  19,850
  20,773
  21,746
  22,771
  23,852
  24,989
  26,187
  27,447
  28,774
  30,169
  31,636
  33,179
Revenue / Adjusted assets
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
  0.771
Average production assets, $m
  1,944
  1,993
  2,046
  2,105
  2,171
  2,242
  2,320
  2,404
  2,494
  2,591
  2,694
  2,805
  2,922
  3,047
  3,179
  3,319
  3,467
  3,624
  3,789
  3,964
  4,148
  4,342
  4,547
  4,763
  4,990
  5,229
  5,481
  5,746
  6,024
  6,317
  6,626
Working capital, $m
  550
  200
  205
  211
  218
  225
  233
  241
  250
  260
  270
  282
  293
  306
  319
  333
  348
  364
  380
  398
  416
  436
  456
  478
  501
  525
  550
  577
  605
  634
  665
Total debt, $m
  3,734
  3,861
  4,010
  4,177
  4,360
  4,561
  4,779
  5,015
  5,269
  5,541
  5,831
  6,141
  6,471
  6,821
  7,193
  7,586
  8,002
  8,442
  8,907
  9,398
  9,916
  10,461
  11,037
  11,643
  12,281
  12,953
  13,660
  14,404
  15,187
  16,010
  16,875
Total liabilities, $m
  5,472
  5,599
  5,748
  5,915
  6,098
  6,299
  6,517
  6,753
  7,007
  7,279
  7,569
  7,879
  8,209
  8,559
  8,931
  9,324
  9,740
  10,180
  10,645
  11,136
  11,654
  12,199
  12,775
  13,381
  14,019
  14,691
  15,398
  16,142
  16,925
  17,748
  18,613
Total equity, $m
  4,628
  4,382
  4,498
  4,628
  4,772
  4,929
  5,100
  5,285
  5,483
  5,696
  5,923
  6,166
  6,424
  6,698
  6,988
  7,296
  7,622
  7,966
  8,330
  8,714
  9,119
  9,546
  9,997
  10,471
  10,970
  11,496
  12,049
  12,632
  13,244
  13,888
  14,566
Total liabilities and equity, $m
  10,100
  9,981
  10,246
  10,543
  10,870
  11,228
  11,617
  12,038
  12,490
  12,975
  13,492
  14,045
  14,633
  15,257
  15,919
  16,620
  17,362
  18,146
  18,975
  19,850
  20,773
  21,745
  22,772
  23,852
  24,989
  26,187
  27,447
  28,774
  30,169
  31,636
  33,179
Debt-to-equity ratio
  0.807
  0.880
  0.890
  0.900
  0.910
  0.930
  0.940
  0.950
  0.960
  0.970
  0.980
  1.000
  1.010
  1.020
  1.030
  1.040
  1.050
  1.060
  1.070
  1.080
  1.090
  1.100
  1.100
  1.110
  1.120
  1.130
  1.130
  1.140
  1.150
  1.150
  1.160
Adjusted equity ratio
  0.438
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439
  0.439

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  645
  952
  988
  1,028
  1,073
  1,121
  1,174
  1,230
  1,291
  1,357
  1,427
  1,939
  2,018
  2,102
  2,192
  2,286
  2,386
  2,492
  2,603
  2,721
  2,845
  2,976
  3,114
  3,260
  3,413
  3,574
  3,744
  3,923
  4,110
  4,308
  4,516
Depreciation, amort., depletion, $m
  249
  666
  668
  670
  672
  675
  677
  680
  683
  686
  690
  93
  97
  102
  106
  111
  116
  121
  126
  132
  138
  145
  152
  159
  166
  174
  183
  192
  201
  211
  221
Funds from operations, $m
  849
  1,619
  1,656
  1,698
  1,745
  1,796
  1,851
  1,910
  1,975
  2,043
  2,116
  2,033
  2,116
  2,204
  2,298
  2,397
  2,502
  2,613
  2,730
  2,853
  2,984
  3,121
  3,266
  3,419
  3,579
  3,749
  3,927
  4,114
  4,311
  4,518
  4,736
Change in working capital, $m
  -220
  5
  5
  6
  7
  7
  8
  8
  9
  10
  10
  11
  12
  13
  13
  14
  15
  16
  17
  18
  18
  20
  21
  22
  23
  24
  25
  27
  28
  29
  31
Cash from operations, $m
  1,069
  1,614
  1,651
  1,693
  1,738
  1,789
  1,843
  1,902
  1,965
  2,033
  2,106
  2,022
  2,104
  2,191
  2,284
  2,383
  2,487
  2,597
  2,713
  2,836
  2,965
  3,102
  3,245
  3,397
  3,557
  3,725
  3,901
  4,087
  4,283
  4,489
  4,705
Maintenance CAPEX, $m
  0
  -65
  -66
  -68
  -70
  -72
  -75
  -77
  -80
  -83
  -86
  -90
  -93
  -97
  -102
  -106
  -111
  -116
  -121
  -126
  -132
  -138
  -145
  -152
  -159
  -166
  -174
  -183
  -192
  -201
  -211
New CAPEX, $m
  -293
  -50
  -53
  -59
  -65
  -72
  -78
  -84
  -90
  -97
  -103
  -110
  -117
  -125
  -132
  -140
  -148
  -157
  -165
  -175
  -184
  -194
  -205
  -216
  -227
  -239
  -252
  -265
  -279
  -293
  -308
Cash from investing activities, $m
  -152
  -115
  -119
  -127
  -135
  -144
  -153
  -161
  -170
  -180
  -189
  -200
  -210
  -222
  -234
  -246
  -259
  -273
  -286
  -301
  -316
  -332
  -350
  -368
  -386
  -405
  -426
  -448
  -471
  -494
  -519
Free cash flow, $m
  917
  1,500
  1,532
  1,565
  1,603
  1,645
  1,691
  1,741
  1,795
  1,853
  1,916
  1,821
  1,893
  1,969
  2,051
  2,137
  2,228
  2,325
  2,427
  2,535
  2,649
  2,769
  2,896
  3,030
  3,171
  3,319
  3,475
  3,640
  3,813
  3,995
  4,187
Issuance/(repayment) of debt, $m
  145
  133
  149
  166
  184
  201
  218
  236
  254
  272
  291
  310
  330
  350
  371
  393
  416
  440
  465
  491
  518
  546
  575
  606
  638
  672
  707
  744
  783
  823
  866
Issuance/(repurchase) of shares, $m
  -517
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -468
  133
  149
  166
  184
  201
  218
  236
  254
  272
  291
  310
  330
  350
  371
  393
  416
  440
  465
  491
  518
  546
  575
  606
  638
  672
  707
  744
  783
  823
  866
Total cash flow (excl. dividends), $m
  449
  1,633
  1,680
  1,731
  1,786
  1,846
  1,909
  1,977
  2,049
  2,125
  2,207
  2,131
  2,223
  2,320
  2,422
  2,530
  2,644
  2,765
  2,892
  3,025
  3,166
  3,315
  3,471
  3,636
  3,809
  3,991
  4,183
  4,384
  4,596
  4,818
  5,052
Retained Cash Flow (-), $m
  56
  -107
  -117
  -130
  -144
  -157
  -171
  -185
  -199
  -213
  -227
  -242
  -258
  -274
  -291
  -308
  -326
  -344
  -364
  -384
  -405
  -427
  -450
  -474
  -499
  -526
  -553
  -582
  -612
  -644
  -677
Prev. year cash balance distribution, $m
 
  353
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  1,879
  1,564
  1,601
  1,643
  1,688
  1,738
  1,792
  1,850
  1,913
  1,979
  1,889
  1,965
  2,046
  2,131
  2,222
  2,318
  2,420
  2,528
  2,641
  2,761
  2,888
  3,021
  3,162
  3,309
  3,465
  3,629
  3,802
  3,983
  4,174
  4,375
Discount rate, %
 
  6.00
  6.30
  6.62
  6.95
  7.29
  7.66
  8.04
  8.44
  8.86
  9.31
  9.77
  10.26
  10.78
  11.31
  11.88
  12.47
  13.10
  13.75
  14.44
  15.16
  15.92
  16.72
  17.55
  18.43
  19.35
  20.32
  21.33
  22.40
  23.52
  24.70
PV of cash for distribution, $m
 
  1,773
  1,384
  1,321
  1,256
  1,187
  1,116
  1,043
  967
  891
  813
  677
  608
  541
  475
  413
  354
  299
  249
  204
  164
  130
  101
  77
  57
  42
  30
  21
  14
  9
  6
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

FINANCIAL RATIOS  of  Quest Diagnostics (DGX)

Valuation Ratios
P/E Ratio 20.2
Price to Sales 1.7
Price to Book 2.8
Price to Tangible Book
Price to Cash Flow 12.2
Price to Free Cash Flow 16.8
Growth Rates
Sales Growth Rate 0.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 11.4%
Cap. Spend. - 3 Yr. Gr. Rate 4.9%
Financial Strength
Quick Ratio 60
Current Ratio 0
LT Debt to Equity 80.6%
Total Debt to Equity 80.7%
Interest Coverage 9
Management Effectiveness
Return On Assets 7.3%
Ret/ On Assets - 3 Yr. Avg. 7.6%
Return On Total Capital 7.7%
Ret/ On T. Cap. - 3 Yr. Avg. 7.9%
Return On Equity 13.9%
Return On Equity - 3 Yr. Avg. 14.4%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 39.4%
Gross Margin - 3 Yr. Avg. 38.5%
EBITDA Margin 20.3%
EBITDA Margin - 3 Yr. Avg. 19.9%
Operating Margin 17%
Oper. Margin - 3 Yr. Avg. 16.3%
Pre-Tax Margin 15%
Pre-Tax Margin - 3 Yr. Avg. 13.8%
Net Profit Margin 8.6%
Net Profit Margin - 3 Yr. Avg. 8.5%
Effective Tax Rate 38.1%
Eff/ Tax Rate - 3 Yr. Avg. 34%
Payout Ratio 34.6%

DGX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DGX stock intrinsic value calculation we used $7515 million for the last fiscal year's total revenue generated by Quest Diagnostics. The default revenue input number comes from 2016 income statement of Quest Diagnostics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DGX stock valuation model: a) initial revenue growth rate of 2.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6%, whose default value for DGX is calculated based on our internal credit rating of Quest Diagnostics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Quest Diagnostics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DGX stock the variable cost ratio is equal to 81.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for DGX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4% for Quest Diagnostics.

Corporate tax rate of 27% is the nominal tax rate for Quest Diagnostics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DGX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DGX are equal to 25.9%.

Life of production assets of 31.7 years is the average useful life of capital assets used in Quest Diagnostics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DGX is equal to 2.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $4628 million for Quest Diagnostics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 136.306 million for Quest Diagnostics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Quest Diagnostics at the current share price and the inputted number of shares is $13.0 billion.

RELATED COMPANIES Price Int.Val. Rating
LH Laboratory of 151.72 145.26  hold
PMD Psychemedics 16.75 20.02  hold
NEO NeoGenomics 8.84 1.26  str.sell
CBMX CombiMatrix 7.95 95.13  str.buy
ENZ Enzo Biochem 9.98 13.20  buy
OPK OPKO Health 6.96 0.62  str.sell
OPGN OpGen 0.360 0.01  str.sell
CGIX Cancer Genetic 2.75 0.18  str.sell

COMPANY NEWS

▶ Quest Diagnostics tops Street 3Q forecasts   [07:13AM  Associated Press]
▶ How proposed cuts to Medicare reimbursement rates could impact LabCorp   [Sep-26-17 05:40PM  American City Business Journals]
▶ The Big Loser: Quest Diagnostics Quits   [Sep-25-17 04:34PM  Barrons.com]
▶ Quest Diagnostics: Will It Fail The Test?   [10:40AM  Barrons.com]
▶ Quest Diagnostics tops 2Q profit forecasts   [Jul-25-17 09:57PM  Associated Press]
▶ Gold ETF Backs Away From Buy Point; Financials Soar   [Jun-08-17 12:39PM  Investor's Business Daily]
▶ Quest Diagnostics Pushes Beyond Lab Tests With Treatment Prediction   [May-26-17 04:11PM  The Wall Street Journal]
Financial statements of DGX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.